TAPISTRY trial: what clinicians have said so far
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
- NCT04589845 ↗
- Active, not recruiting
- Hoffmann-La Roche
- Standard size, estimated: 151–300 verified statements once built
Discussed at: 2026 ASCO Annual Meeting, ESMO Congress 2026
We haven't built an HCP commentary report on TAPISTRY (entrectinib; alectinib; atezolizumab in solid tumors) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on TAPISTRY so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 11 posts on X, typically up to 48 once built | |
| 1 YouTube video, typically up to 4 once built | |
| 1 podcast episode, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Solid Tumors
- Interventions
- Entrectinib; Entrectinib; Alectinib; Atezolizumab; Ipatasertib; Trastuzumab emtansine; Inavolisib; Belvarafenib; Pralsetinib; Divarasib; Camonsertib
- Arms
- Cohort A: ROS Proto-oncogene 1 (ROS1) Fusion-positive Tumors (Excluding NSCLC) · Experimental
- Cohort B: Neurotrophic Tyrosine Receptor Kinase (NTRK) 1/2/3 Fusion-positive Tumors · Experimental
- Cohort C: Anaplastic Lymphoma Kinase (ALK) Fusion-positive Tumors (Excluding NSCLC) · Experimental
- Cohort D: TMB-high Tumors · Experimental
- Cohort E: Protein Kinase B (AKT) 1/2/3 Mutant-positive Tumors · Experimental
- Cohort F: Human Epidermal Growth Factor Receptor 2 (HER2) Mutant-positive Tumors · Experimental
- Cohort H: PIK3CA Multiple Mutant-positive Tumors · Experimental
- Cohort I: BRAF Class II Mutant or Fusion-positive Tumors · Experimental
- Cohort J: BRAF Class III Mutant-positive Tumors · Experimental
- Cohort K: Rearranged During Transfection (RET) Fusion-positive Tumors (Excluding NSCLC) · Experimental
- Cohort L: KRAS G12C-positive Tumors (Excluding NSCLC and Colorectal Cancer [CRC]) · Experimental
- Cohort M: Ataxia-telangiectasia Mutated (ATM) Loss of Function (LOF) Tumors · Experimental
- Cohort N: SETD2 LOF Tumors · Experimental
- Enrollment
- 920 (estimated)
- Primary outcomes
- All Cohorts: Independent Review Committee (IRC)-assessed Objective Response Rate (ORR) Based on Confirmed Objective Response (OR) per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1)
- Sponsor
- Hoffmann-La Roche
- Start
- Jan 18, 2021
- Primary completion
- Sep 25, 2032 (estimated)
- Results posted
- No
- Registry record
- NCT04589845 · updated Sep 4, 2026
Publications
linked from the registry- Bagchi A, Chiang J, Pinto S, Dhanda S, Gajjar A. Infant-Type Hemispheric Gliomas: A Review of Clinical, Radiologic, Histopathologic, and Molecular Features. J Natl Compr Canc Netw. 2025 Nov;23(11):e257064. doi: 10.6004/jnccn.2025.7064. PubMed 41213248
- Desai AV, Bagchi A, Armstrong AE, van Tilburg CM, Basu EM, Robinson GW, Wang H, Casanova M, Andre N, Campbell-Hewson Q, Wu Y, Cardenas A, Ci B, Ryklansky C, Devlin CE, Meneses-Lorente G, Wulff J, Hutchinson KE, Gajjar A, Fox E. Efficacy and safety of entrectinib in children with extracranial solid or central nervous system (CNS) tumours harbouring NTRK or ROS1 fusions. Eur J Cancer. 2025 May 2;220:115308. doi: 10.1016/j.ejca.2025.115308. Epub 2025 Feb 22. PubMed 40086048